Chronic Rejection  by Libby, Peter & Pober, Jordan S.
Immunity, Vol. 14, 387–397, April, 2001, Copyright ª 2001 by Cell Press
Chronic Rejection Review
is the actual incidence of chronic rejection as a causePeter Libby*‡ and Jordan S. Pober†
*Division of Cardiovascular Medicine of late graft loss? Second, what are the immunological
mechanisms that underlie chronic rejection? Third, howBrigham and Women’s Hospital
Boston, Massachusetts 02115 do these immunological mechanisms relate to other
forms of graft injury? Fourth, what have we learned from†Interdepartmental Program in Vascular Biology
and Transplantation experimental and/or clinical studies of chronic rejec-
tion? And fifth, how might chronic rejection be preventedYale University School of Medicine
New Haven, Connecticut 06520 or treated?
Introduction The Relationship of Chronic Rejection
In allograft rejection, the recipient’s immune system rec- to Late Graft Failure
ognizes the donor’s tissue as foreign and attacks the As noted earlier, the incidence of late graft failure in
graft. In the absence of immunosuppression, a rejecting the three commonly transplanted solid organs (kidney,
solid organ (vascularized) graft characteristically con- heart, and liver) is about 3%–5% each year posttrans-
tains dense infiltrates of host leukocytes, which cause plantation (Cecka, 1999; Keck et al., 1999; Smith et al.,
graft cell necrosis and/or graft vessel thrombosis. In 1999). Since not all late graft failure is due to chronic
hosts not previously exposed to graft alloantigens, this rejection, this number sets a ceiling upon the true inci-
response, called acute rejection, typically occurs 1–2 dence of chronic rejection. Of the three commonly trans-
weeks following transplantation. Immunosuppressive planted solid organs, the relationship of chronic rejec-
agents may prevent or reverse most acute rejection epi- tion to late graft failure seems most clear for heart
sodes. However, even though these agents limit acute allografts.
rejection, the graft may still succumb to a more insidious In cardiac transplantation, the graft arterial tree fre-
type of chronic rejection characterized by replacement quently undergoes pathological remodeling character-
fibrosis of the graft parenchyma developing over months ized by progressive lumenal narrowing (Julius et al.,
to years. The precise relationship between acute and 2000). These changes occur independently of biopsy-
chronic rejection remains uncertain. However, acute re- diagnosed episodes of acute parenchymal rejection.
jection episodes, even when completely reversed by Cardiac allograft vascular remodeling develops over
immunosuppressive treatment, increase the likelihood months to years, stops at the suture line, and frequently
that chronic rejection will develop (Matas et al., 1994). affects vessels that show no histological evidence of
Despite the availability of effective immunosuppres- prior injury. As we will discuss shortly, experimentally
sive regimens for acute rejection, kidney and heart allo- progressive vascular remodeling occurs in allogeneic
grafts currently fail at a rate of about 5% each year but not syngeneic cardiac grafts, implying a central role
posttransplantation (Cecka, 1999; Keck et al., 1999). He- of alloreactivity in generating the human lesions. By
patic allografts also fail progressively, although at a these criteria, pathological cardiac allograft arterial ste-
somewhat lower rate (Smith et al., 1999). Remarkably, nosis fits our definition of alloimmune-mediated chronic
while graft loss due to acute rejection has steadily re- vascular rejection. Descriptive terms for this lesion
ceded to less than 10%, the introduction of new immu- abound, among them transplant-associated acceler-
nosuppressive agents and regimens has not signifi- ated arteriosclerosis, graft arteriosclerosis, and graft or
cantly altered the incidence of late graft loss. Many transplant vasculopathy.
equate delayed graft failure with chronic rejection, but While some degree of graft vascular remodeling, as
this imprecise use of the term may both overestimate assessed by mural thickening of epicardial coronary
the incidence and obscure the nature of the chronic arteries, occurs in all graft recipients, not all patients
rejection process. We here restrict chronic rejection to show progressive arterial lumen loss. In other words,
mean late graft loss caused by a host-anti-graft immune clinically significant chronic vascular rejection occurs in
response. We also adopt the prognostically meaningful only a subset of heart transplant recipients. However,
practice of separating parenchymal cell from vascular patients with late failing heart allografts almost always
rejection. Thus, we define chronic parenchymal cell re- show extensive graft arterial and arteriolar lumen loss
jection to mean graft failure due to progressive immune- (Billingham, 1994). Such hearts also show replacement
mediated replacement fibrosis of graft parenchyma and fibrosis of the parenchyma, and this myocardial fibrosis
chronic vascular rejection to mean stenosis of vessels in failing cardiac allografts rarely if ever occurs without
(particularly arteries and arterioles) due to a progressive arterial lumen loss. In contrast, acute parenchymal rejec-
immune-mediated host response to the graft blood ves- tion frequently occurs in the absence of acute vascular
sels. We distinguish both types of chronic rejection from rejection, and this linked relationship of chronic vascular
repair that may follow injury from acute rejection or from rejection to parenchymal fibrosis would not be expected
ischemia or other causes. if parenchymal fibrosis resulted from chronic parenchy-
This review will address several questions. First, what mal rejection rather than as a consequence of ischemia
due to chronic vascular rejection. In other words, the
vascular changes of late failing heart grafts do represent‡ To whom correspondence should be addressed (e-mail: plibby@
rics.bwh.harvard.edu). chronic rejection, but the parenchymal changes do not.
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Analogy with other forms of heart disease supports this The Biology of Chronic Vascular Rejection
As we have just described, chronic vascular rejectioninterpretation of causality. For example, severe arterial
stenosis due to atherosclerosis in native hearts can results in a decrease in caliber of the arterial lumena
that ultimately leads to the ischemia that causes latecause myocardial fibrosis, whereas myocardial fibrosis
due to primary myocyte injury (myocarditis or cardiomy- graft failure. Understanding the pathogenesis of lumen
loss requires a review of the structure of a normal humanopathy) independently of vascular disease does not
cause arterial lumen loss. artery (Figure 1A). The innermost layer, the intima, con-
sists of a monolayer of endothelial cells residing on aStudies of hepatic allografts support the generality of
the conclusion that chronic vascular rejection rather thin layer of extracellular matrix and occasional smooth
muscle cells, bounded ablumenally by the internal elas-than chronic parenchymal rejection causes parenchy-
mal replacement fibrosis in late failing allografts. In this tic lamina. Normally, the intimal layer is far thinner than
the next layer of the artery, known as the tunica media.setting, most instances of late graft loss are character-
ized by “disappearance” of the bile ducts, an example The media consists of layers of arterial smooth muscle
cells embedded in an elastin- and collagen-rich extra-of replacement fibrosis, and this often occurs in liver
allografts in which the hepatocytes are generally pre- cellular matrix. The media is bounded ablumenally by
the external elastic lamina. The outermost layer of theserved (Wersner et al., 1999). Chronic vascular rejection
of the hepatic artery and its branches almost always artery, the adventitia, consists of occasional myofi-
broblasts, autonomic nerve endings, a few leukocytes,accompanies bile duct loss. The bile ducts depend on
the hepatic artery exclusively for nutrition, whereas the and extracellular matrix. Although restriction of the lu-
men can arise from several causes, most have attributedhepatic cords enjoy a dual blood supply arising from
both the hepatic artery and the portal vein. The addi- lumen loss in graft arteriosclerosis to thickening of the
intima, the innermost layer of the artery (Figure 1B).tional portal venous perfusion thus explains sparing of
hepatic cords from the consequences of chronic hepatic Intimal thickening results from migration of smooth mus-
cle cells into the intima from the media and/or prolifera-artery rejection, whereas the bile ducts in the same graft
succumb. This pattern of injury therefore suggests that tion of resident or migratory smooth muscle cells and
elaboration of extracellular matrix. Leukocytes recruitedin liver transplantation, as in heart transplantation,
chronic vascular rejection is the primary cause of late in response to injury or inflammation also populate the
thickened intima in graft arteriosclerosis (Hruban et al.,graft loss and parenchymal fibrosis.
Are other organs different? Many renal transplanters 1990; Salomon et al., 1991).
Human studies have recently used a novel imagingthink so, citing epidemiological evidence that nonim-
mune factors, especially organ condition (e.g., living ver- technique, intravascular ultrasound, to obtain cross-
sectional images of arteries in vivo (similar to the viewssus cadaver donor, donor age, etc.), strongly predict
late graft loss (Cecka, 1998). However, this view cannot shown in Figure 1). In the context of transplanted arter-
ies, intravascular ultrasound has proven very revealingreadily explain the common occurrence of arterial and
arteriolar lumen loss in late failing renal grafts (Cosio et (Kapadia et al., 1999). First, these studies have shown a
surprising incidence of transfer of donor atherosclerosisal., 1999) but not in chronically failing native kidneys. In
other words, anatomic findings favor the idea that into recipients (Tuzcu et al., 1995). Indeed, even the
coronary arteries of young donors lacking known riskchronic vascular rejection underlies many instances of
late renal allograft loss. It is also worth noting that late factors for usual atherosclerosis can have considerable
atherosclerotic disease. Their lesions are often clinicallylung allograft loss, associated with bronchiolar oblitera-
tion (bronchiolitis obliterans), is generally accompanied inapparent because of a compensatory enlargement of
the artery preserving the lumenal caliber and preventingby pulmonary arterial lumen loss and that the vascular
changes, exacerbated by absence of bronchial artery ischemia, or lack of flow. Second, intravascular ultra-
sound studies have also shown that a shrinkage of theperfusion, may also be the primary event in this organ
as well (Epler and Colby, 1983). arteries due to adventitial scarring, known as negative
or constrictive remodeling, can contribute to loss ofIf most late graft loss and parenchymal replacement
fibrosis is due to chronic vascular rejection (at least for lumen in transplanted arteries (Figure 1C) (Lim et al.,
1997; Schwarzacher et al., 2000). During allograft rejec-hearts and livers), is chronic parenchymal rejection a
real entity? It probably does occur in kidney transplanta- tion, T lymphocytes and macrophages can surround
vessels, a histologic feature of parenchymal rejectiontion, but the incidence is hard to assess. Some kidney
grafts do show parenchymal fibrosis without vascular known as “perivascular cuffing” (Figure 2). Mediators
elaborated by these leukocytes may produce local injurychanges, but it is not clear whether these cases actually
represent isolated chronic parenchymal cell rejection or and augment extracellular matrix synthesis. The ensuing
healing response recapitulates wound contractionnonimmune mediated graft failure. A recent experimen-
tal model of chronic rejection in an avascular skin graft around the perimeter of arteries and can lead to an
irreversible “cicatrization” of the vessel, resulting in asystem may be interpreted to support the notion of allo-
immune-mediated replacement fibrosis of parenchyma fixed restriction of the lumen. Some investigators have
argued that constrictive remodeling may be a more sig-(Le Moine et al., 1999). Unexpectedly, vessels feeding
the graft, presumably of host origin, appear to undergo nificant cause of chronic vascular rejection than intimal
expansion (Pethig et al., 1998). The crucial role of nega-pathological remodeling, possibly as a bystander re-
sponse to host-anti-graft rejection taking place in the tive remodeling in the setting of transplantation is mir-
rored in other forms of vascular disease, such as athero-surrounding graft tissue. Thus, even in this model, vas-
cular changes may be the primary event leading to graft sclerosis and restenosis following balloon angioplasty
(Mintz et al., 1996).fibrosis.
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Figure 1. Arterial Remodeling in Chronic
Vascular Rejection
(A) A schematic of a normal artery. The blue
area represents the lumen, or blood flow
channel. The yellow ring represents the inti-
mal layer, bounded on its lumenal surface by
a monolayer of vascular endothelial cells. The
internal elastic membrane demarcates the
border between the intima and the medial
layer. The media, in red, is comprised primar-
ily of smooth muscle cells and extracellular
matrix molecules such as elastin. The exter-
nal elastica demarcates the boundary be-
tween the medial and adventitial layer of
arteries. The speckled outermost ring repre-
sents the adventitia, usually made up of loose
connective tissue and occasional fibroblasts.
(B) Shows intimal thickening (a widened yel-
low layer) that has produced a narrowing of
the flow channel (a stenosis, blue). This re-
sembles the situation shown in the photomi-
crograph of Figure 3.
(C) Depicts constrictive remodeling. In this
situation, a healing response in the adventitia
has squeezed the media and intima inward,
causing a lumenal stenosis. The wavy lines surrounding the adventitia represent collagen fibrils in the “scar tissue” that has formed in response
to perivascular inflammation (see Figure 2), leading to cicatrization that causes the constrictive remodeling.
(D) Shows vasoconstriction due to contraction of the smooth muscle cells in the tunica media. This excessive contraction of smooth muscle
cells may result from impaired endogenous vasodilator activity (e.g., nitric oxide) elaborated by dysfunctional or injured endothelial cells in
the intima, for example, in response to acute rejection. The stellate appearance of the intima represents the “accordioning” of the intimal
layer when squeezed by the smooth muscle cells. The bidirectional arrow indicates that vasoconstriction may be dynamic, relieved by relaxation
of the smooth muscle layer, due to pharmacologic intervention or restored endothelial vasodilator function.
In addition to fixed reductions in lumenal diameter due kine-producing “helper” T (TH) lymphocytes, (2) alloreac-
tive CD81 cytolytic T lymphocytes (CTL), and (3) allo-to intimal thickening or negative remodeling, dynamic
reductions in lumen caliber can occur because of im- reactive antibodies (produced by B lymphocytes) (Auch-
incloss and Sachs, 1993).paired vasodilatation or vasoconstriction (Figure 1D)
(Davis et al., 1996). The smooth muscle cells in the media CD41 T Cell Responses
CD41 T cells have been widely implicated in experimen-of normal human arteries receive tonic vasodilatory
stimuli due to the constitutive production of the endoge- tal parenchymal cell and vascular rejection reactions.
Such cells, activated by recognition of alloantigens, cannous vasodilator nitric oxide by healthy endothelium.
Human transplantation patients show blunted vaso- contribute to rejection in three ways: (1) by provision of
signals that promote the generation of CD81 CTL, eitherdilator responses when challenged with endothelium-
dependent vasodilators. Episodes of acute rejection directly to the CTL (e.g., by secreting IL-2) or by activat-
ing (“licensing”) dendritic cells to promote CTL differen-may exacerbate these impaired responses (Davis et al.,
1996). Thus, endothelial injury may counteract an endog- tiation; (2) by provision of signals (referred to as “help”)
that promote differentiation and activation of alloanti-enous vasodilatory mechanism, setting the stage for
adding a dynamic (reversible) vasoconstrictive compo- body-producing B cells; and (3) by activating antigen-
independent effector leukocytes, which damage the tissuenent to the arterial narrowing produced by fixed archi-
tectural changes, such as intimal thickening or constric- (Lowry, 1996). The best-characterized effector leuko-
cytes in CD41 T cell–mediated reactions are activatedtive remodeling (indicated by the bidirectional arrows in
Figure 1D). Many of these same alterations characterize macrophages, which damage tissue through release of
mediators such as reactive oxygen intermediates, nitricordinary atherosclerosis. However, graft arteriosclerosis
tends to produce lesions that are more concentric and oxide, and degradative enzymes. In host defense reac-
tions, these mediators serve a protective function bydiffuse, rather than eccentric and focal (Figure 3). More-
over, in graft arteriosclerosis, the involvement extends eradicating foreign microbes. Indeed, CD41 T cell–
mediated activation of macrophages is the characteris-beyond the larger conduit arteries to the penetrating
smaller ramifications. These distinctions highlight the tic mechanism of cell-mediated immunity (CMI) against
infection by intracellular bacteria (Kaufmann, 1993). Nor-challenge of graft arteriosclerosis, which, because of its
diffuse and distal distribution, evades usual revasculari- mal tissues as well as microbes are damaged in this
setting, but the overall reaction is deemed protectivezation strategies such as bypass surgery or percutane-
ous balloon angioplasty or stenting. because the animal (or patient) will die if macrophage
activation is impaired. When the same effector mecha-
nisms are activated by an antigen not associated withImmunological Mechanisms of Chronic
Vascular Rejection a pathogenic microbe, the resultant tissue injury is no
longer part of a protective reaction, and it is commonlyThree potential effector mechanisms have been impli-
cated in allograft rejection: (1) alloreactive CD41 cyto- called delayed-type hypersensitivity (DTH) (Black, 1999).
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Acute DTH has been invoked as a possible mechanism
of acute allograft rejection (Sirak et al., 1997).
If the antigen that elicits DTH is not eliminated, then
CD41 T cells and macrophages will remain persistently
activated and release cytokines and growth factors that
act on mesenchymal cells to promote stromal cell
growth and fibrosis. In chronic infections, fibrosis may
protect the host by walling off microbes from the rest
of the body. However, as in acute CMI, if the antigen is
not related to an infectious agent, the fibrosing reaction
is not protective and is referred to as chronic DTH. When
the persistent foreign antigen is an allograft, chronic
DTH is a possible mechanism of chronic rejection (Salo-
mon et al., 1991).
Transplantation immunologists have recently pon-
dered whether the alloreactive CD41 T cells respond
directly to graft cells (which can directly “present” for-
eign MHC class II molecules in an unprocessed form to
a subset of alloreactive CD41 T cells) or whether they
are reacting to peptides derived from graft alloantigens
(such as MHC molecules) that are presented by host
dendritic cells in association with self-MHC class II mol-
ecules, a pathway called indirect presentation (Gould
and Auchincloss, 1999). In general, alloreactive T cell
clones that respond to direct presentation of foreign
MHC molecules are distinct from those that are acti-
vated by indirect presentation, and, in the immediate
posttransplant period, direct presentation of alloantigen
predominates because T cells capable of responding
to direct presentation of foreign MHC molecules vastly
outnumber those that respond to indirect presentation.
The earliest antigraft response involves the activation
Figure 2. Coronary Arterial Inflammation in an Experimental Cardiac
of preexisting alloreactive memory T cells (which areAllograft
present because of prior stimulation of the immune sys-Hearts from a Dutch Belted rabbit were transplanted into the neck
tem by microbes whose peptides bound to self-MHCof a recipient New Zealand White rabbit. The donor aorta was anas-
molecules mimic the determinants displayed by foreigntomosed to the recipient carotid artery, and the donor pulmonary
artery was anastomosed to the recipient jugular vein. The animals MHC molecules). Human endothelial cells can directly
received cyclosporine (5 mg/kg per day) as immunosuppressive present alloantigens to these memory CD41 T cells
treatment. The top panel shows a cross section of an epicardial (Pober et al., 1996), and such responses can be initiated
coronary artery. The adventitia of this artery contains a lymphocytic within the graft itself either by graft endothelium or den-
infiltrate from approximately three o’clock to seven o’clock, stained
dritic cells (passenger leukocytes). The response of na-brown to reveal the presence of T cells. Some T cells are also seen
ive CD41 T cells is slower than that of memory cells andin the intima opposite the eccentric adventitial T cell aggregate. The
may be initiated either by direct presentation of intactlower panel is stained for macrophages (M`). Note the prominent
accumulation of macrophages in and overlying the intima opposite foreign MHC molecules by graft-derived dendritic cells
the eccentric collection of T cells in the adventitia. The adventitial or by indirect presentation of peptides derived from allo-
inflammation may contribute to cicatrix formation and constrictive, antigens by host dendritic cells. However, naive cells
inward remodeling of chronic vascular rejection. These photomicro- can only be activated within the microenvironment of the
graphs were obtained at 6 weeks following transplantation. The
secondary lymphoid organs where they must expandsurrounding myocardium shows little evidence of acute rejection.
before migrating to the graft. Therefore, alloantigensPhotomicrograph courtesy of Hiroyuki Tanaka, MD, Ph.D.
must travel from the graft to the lymphoid organs to
activate naive T cells. This is why naive T cells cannot
(“Delayed” refers to the fact that induration slowly devel- reject an allograft in the absence of secondary lymphoid
ops over 24–48 hr, and “hypersensitivity” refers to inap- organs (Lakkis et al., 2000). Once naive T cells have
propriate damage of tissues by the immune system.) undergone activation and clonal expansion, they can
Histopathologically, DTH develops as perivascular ac- contribute to and may, in some cases, dominate later
cumulations of inflammatory cells, primarily neutrophils responses. Thus, indirect recognition may be important
early and T cells and macrophages later. Inflammation for late events such as chronic rejection reactions (Shir-
in DTH is frequently accompanied by thrombosis, initi- win, 1995; Hornick et al., 2000).
ated by tissue factor expressed either by activated mac- Several different cytokines play important roles in
rophages or by local vascular endothelial cells. In CMI, both acute and chronic CMI/DTH (Lowry, 1996; Black,
thrombosis serves to “wall off” the infectious agent and 1999). These include proinflammatory cytokines such
also may cause ischemic necrosis of the infected site, as tumor necrosis factor (TNF) and lymphotoxin (LT),
whereas, in DTH, thrombosis exacerbates otherwise which are required for the development of inflammatory
infiltrates, as well as macrophage activating factors,healthy tissue injury by causing ischemic infarction.
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Figure 3. Cross-Section of a Human Coronary Artery Affected by Chronic Vascular Rejection
This section has been stained to demonstrate the elastin that demarcates the various layers of arteries. The tunica media, bounded by the
“railroad track” elastin layers of the internal elastic membrane and external elastic membrane, are evident. The markedly expanded intima
actually appears to show two “strata.” The innermost layer appears highly cellular, surrounding the slit-like lumen, and represents the
pathological intimal hyperplasia of chronic vascular rejection. The underlying stratum with scattered elastin fibrils probably represents diffuse
intimal thickening often found in healthy, nonatherosclerotic human coronary arteries. This specimen is oval shaped due to postmortem
compression. It likely had a round lumen and an overall rounder shape when filled with blood at physiologic pressure during life. Photomicro-
graph courtesy of Richard N. Mitchell, MD, Ph.D.
such as interferon-g (IFN-g). IFN-g-elicited chemokines, cells, appears both necessary and sufficient to cause
pathological vascular remodeling in experimental allo-such as interferon-induced protein of 10 kDa (IP-10) and
monokine induced by gamma-interferon (Mig), may also grafts, a model of chronic vascular rejection.
In chronic CD41 T cell responses, it is unclear whatcontribute to CMI/DTH by selectively recruiting IFN-g-
producing T cells. While infiltrating leukocytes probably factors determine whether TH1-, TH2-, or TH3-dominated
responses will develop. Much recent focus has beenproduce most of these mediators, graft cells (especially
graft endothelium) may also elaborate cytokines and placed on cytokines in the environment in which naive
or TH0 cells encounter antigen. This milieu depends in goodchemokines.
Chronically or repeatedly activated CD41 T cells often measure on the innate immune system, comprised of
phagocytes, NK cells, and plasma proteins (Medzhitovpolarize into subsets that selectively (and exclusively)
produce DTH-eliciting cytokines such as IFN-g and LT, and Janeway, 2000). The innate immune system typically
responds to infections by recognizing nonself compo-or eosinophil-activating cytokines such as IL-4, IL-5,
and IL-13, or immunosuppressive cytokines such as IL- nents of microbes through pattern recognition recep-
tors. An example of this is the ability of mannose binding10 and TGF-b (Mosmann and Sad, 1996). Undifferenti-
ated CD41 effector cells that produce complex mixtures lectin (MBL), a plasma protein, to recognize polyman-
nose groups on yeast and, upon binding to the yeastof cytokines are called TH0 cells, the IFN-g/LT-producing
subset of effector cells are called TH1 cells, the IL-4/ surface, activate the classical complement cascade by
substituting for C1 protein. Recently, it has been shownIL-5/IL-13-producing subsets are called TH2 cells, and
the IL-10/TGF-b producing subsets are called TH3 or T that ischemic/reoxygenated endothelial cells display a
previously cryptic endogenous ligand for MBL, whichregulatory (TR) cells. In chronic inflammation, one subset
frequently comes to dominate the response. This com- can bind this protein and activate the complement cas-
cade (Collard et al., 2000). Similarly, human C-reactivepetition is partly explained by the fact that certain
cytokines made by one subset can often suppress the protein, which can activate complement in response to
bacteria, may also do so in response to ischemic injurydifferentiation of the other subsets. Both TH1- and TH2-
dominated reactions become fibrotic as they become (Griselli et al., 1999). In addition, some so-called natural
antibodies, which are IgM molecules reactive with en-chronic. Since TH1 and TH2 subsets cross-inhibit each
other, there are instances (e.g., in chronic schistosomia- dogenous bacterial flora of the gut, may also contribute
to complement activation in tissue ischemia or ische-sis) in which TH1 cells have been described as antifi-
brotic. It does not, however, follow that transplant re- mia/reperfusion by cross-reacting with newly exposed
cryptic antigens (Weiser et al., 1996). In this manner,placement fibrosis is therefore a TH2-type response. In
fact, TH1 cells can be equally profibrotic in other settings injured tissue can activate the innate immune system.
The innate immune system not only provides the first(e.g., tuberculosis or sarcoidosis). Indeed, as we will
describe shortly, IFN-g, the signature cytokine of TH1 line of defense against microbes, but, as we have noted,
Immunity
392
it also can shape the nature of the adaptive immune upon the activation of the complement system and
response that follows (Medzhitov and Janeway, 2000). therefore shares some features with other forms of vas-
The best understood example of this is that monocyte/ cular injury such as ischemia/reperfusion that also in-
macrophages can produce the cytokine IL-12, which volve complement.
stimulates naive or TH0 CD41 T cells to secrete IFN-g There is little direct evidence that either CTL or anti-
and to differentiate into TH1 cells that are specialized to bodies can elicit a chronic rejection pattern, but some
produce IFN-g and LT (Trinchieri, 1998). Inflammatory (or all) chronic rejection could be smoldering, subacute
cytokines such as TNF augment IL-12 production. There- rejection accumulating progressive subclinical (low
fore, the activation of the complement cascade, which level) damage. Since both CD81 CTL and antibodies
leads to TNF release from mast cells and other sources, can cause acute vascular rejection, both could therefore
will favor IL-12 production and promote TH1-dominated contribute to chronic vascular rejection through this
reactions. In transplantation, endogenous activators of mechanism. Some studies have found the presence of
complement, such as those expressed in perioperative antigraft antibodies to correlate with chronic rejection,
ischemia/reperfusion injury, may also favor IL-12 pro- but others have not (Hosenpud et al., 1997; Fredrich et
duction and lead to TH1-dominant reactions. In other al., 1999).
words, local endothelial cell injury can direct the allo-
immune response toward DTH, providing an explanation Nonimmune Contributions to Chronic
of how early ischemia/reperfusion injury within the ves- Vascular Rejection
sel wall can be a risk factor for DTH and chronic vas- Chronic vascular rejection almost certainly results from
cular rejection. (Alloantibodies, which can cause acute pathophysiologic mechanisms in addition to immuno-
vascular rejection, similarly cause complement activa- logical injury discussed above. Notably, perioperative
tion within the vessel wall and may similarly favor devel- ischemia/reperfusion injury can readily explain selective
opment of DTH against graft vessels.) involvement of the transplanted arteries with sparing of
CD81 T Cell and Antibody Responses the host’s own vessels. At the time of explantation of
CD81 T cells may also produce signals that mediate the donor organ, blood flow ceases, and, during the
DTH (especially IFN-g), but these cells primarily damage storage and transport of the organ preceding its reperfu-
grafts by direct cytolysis of graft parenchymal or vascu- sion during the insertion into the recipient, the vascula-
lar cells (Rosenberg and Singer, 1992). Cytolysis must be ture may undergo ischemic injury. Hypoxia, mechanical
exclusively instigated by direct presentation of foreign trauma, and other sorts of nonimmunological injury may
class I molecules by graft cells because alloreactive elicit some of the same proinflammatory responses in-
CTL do not kill bystander cells. Furthermore, only graft volved in immune injury described above. Indeed, ani-
dendritic cells (or endothelial cells) can activate CD81 mal experiments using isografts have shown varying
T cells to differentiate into CTL because host dendritic degrees of arterial responses to the ischemia/reperfu-
cells cannot express the target structure displayed by sion itself, but these do not progress in the absence of
graft cells unless there are shared class I MHC alleles—a allogeneic differences (P. L., unpublished data).
circumstance that actively reduces the strength of rejec-
As noted above, donor arteries often have preexisting
tion reactions. Recent studies have suggested that graft
atherosclerotic lesions that may form a substrate for
endothelial cells may elicit the differentiation of a spe-
accelerated lesion evolution when compounded by allo-
cialized, cell type–specific set of alloreactive CTL (Bied-
geneic injury and/or ischemia/reperfusion. Many heartermann and Pober, 1998, 1999), but the role of these en-
transplantation recipients have a preexisting athero-dothelial-selective killers in acute or chronic vascular
sclerotic diathesis, because end stage atheroscleroticrejection remains speculative. CD81 CTL have recently
disease is the most common indication for heart trans-been identified as the major effector mechanism of acute
plantation. Even individuals who undergo heart trans-parenchymal cell rejection in the clinical setting, i.e., in the
plantation for nonatherosclerotic forms of heart failureface of immunosuppressive agents (Strehlau et al., 1997).
may acquire an atherogenic dyslipidemia posttrans-This may occur because immunosuppressive agents, es-
plantation, in part due to the immunosuppressive drugpecially calcineurin inhibitors such as cyclosporine or ta-
regimen. Thus, accelerated atherosclerosis may con-crolimus, block CD41 T cells more effectively than ef-
tribute to the development of arterial lesions in trans-fector CD81 T cells.
planted organs. Animal experiments have shown poten-Alloantibodies can also cause allograft rejection (Rose,
tiation of hypercholesterolemia-induced atherosclerosis1994). Such antibodies generally recognize the MHC
due to the allogeneic state (Tanaka and Sukhova, 1994).molecules expressed by graft endothelial cells, although
Transplantation recipients may have accentuation ofendothelial-specific non-MHC alloantigens or endothe-
various classical risk factors for atherosclerosis. For ex-lial-monocyte alloantigens may on occasion contribute.
ample, cyclosporine may cause hypertension due to aSince endothelial cells are the principal target cell type,
calcineurin-mediated alteration in autonomic tone con-antibody-initiated rejection is primarily vascular rejec-
trolling systemic blood pressure (Lyson et al., 1993).tion. Indeed vascular rejection was initially called hu-
Transplantation recipients, because of their immuosup-moral rejection until it was appreciated that CTL could
pressed state, have heightened susceptibility to infec-also contribute, especially to early vascular rejection
tions (Hosenpud, 1999). Some evidence supports anlesions referred to as intimal arteritis or endothelialitis
association between primary or reactivated infections(Meehan et al., 1997). (Although “endothelitis” would
with cytomegalovirus (CMV) and allograft arteriosclero-be a more correct term, “endothelialitis” is now firmly
sis (Grattan et al., 1989). However, seroepidemiologicensconced in the transplant literature.) The damage of
graft endothelium produced by alloantibody depends associations between a common infection (CMV) and a
Review
393
Figure 4. Vascular Injury from a Variety of
Causes May Directly Cause Pathological Ar-
terial Remodeling
In the arteries of an allografted organ, endo-
thelial injury may arise from immune injury
(rejection), ischemia/reperfusion injury, injury
due to dyslipidemia, injury due to hyperten-
sion, or injury due to infectious agents (see
text for full explanation). The injured endothe-
lial cell can elaborate small molecules and
cytokines that can activate macrophages and
smooth muscle cells to express functions
that may contribute to arterial lesion forma-
tion. In this model, chronic vascular rejection
is a response to injury caused by smoldering
acute vascular rejection and other factors
that may exacerbate this response by in-
creasing the total burden of injury.
common complication of transplantation (development a recipient with a donor graft. However, the transplanted
aortas usually undergo necrosis of the tunica mediaof graft arteriosclerosis) have rendered it difficult to es-
(Bigaud et al., 1999). While this model is appropriate fortablish causality between infection and development of
study of vascular repair, it does not provide a suitableor potentiation of graft arterial disease.
mimic of the human chronic vascular rejection. SomeWhile these various forms of injury can each indepen-
have used loops of donor artery sewn end-to-side to adently cause arterial lumen loss, the strength of the
recipient artery (Shi et al., 1994). This preparation mayalloreaction in transplantation may overwhelm all other
involve some early thrombosis in the lumen, followedissues. In this context, nonimmunological risk factors
by healing. Analysis of the parts of the loop near themay function as immune modifiers. Various forms of
anastomotic sites may be confounded by altered hemo-injury have in common the capacity to elicit inflamma-
dynamics. In addition, these structures lack a sur-tion. Such inflammation, as we have already described
rounding parenchyma and thus do not provide a perfectfor ischemia-reperfusion injury, may act to favor TH1-
mimic of the solid organ graft arteriosclerosis. However,like-dominated alloresponses over TH2-like responses.
such preparations have proven useful in defining certainThese two alternative contributions of nonimmune injury
immunological mechanisms of graft arterial disease (Shito chronic vascular rejection are depicted in Figures 4
et al., 1996).and 5.
Grafting of whole hearts heterotopically (for example
into the abdomen of a recipient mouse) with anastomo-
Animal Models of Chronic Vascular Rejection sis of the great vessels to those of the recipient provides
As noted above, various animal models have proven a technically challenging but feasible model of cardiac
useful in discerning potential pathophysiologic mecha- transplantation. Transplantation of hearts across major
nisms contributing to graft arteriosclerosis. Early studies histocompatibility barriers does lead to development
used large animals, including the rabbit, to study allo- of graft arteriosclerosis, with time resembling in many
graft arteriopathy. However, due to the lack of congenic respects the human lesion. Various types of immuno-
strains and paucity of appropriate reagents, larger ani- suppression limit early graft failure due to acute paren-
mals, while tractable to transplantation surgery, have chymal rejection. Such models have been particularly
considerable limitations as experimental models. Much informative in mice where transgenic and “knockout”
recent work has shifted to rodents, particularly mice, animals permit exploration of mechanisms. These car-
because of the availability of many useful reagents, well- diac allografts nonetheless have certain limitations. Al-
characterized inbred strains, and relative ease of genetic though the coronary arteries are perfused, the ventricu-
manipulation. Although the microsurgery requires con- lar chambers do not subserve a usual pumping function
siderable prowess, many laboratories have successfully and often develop an intracavitary thrombus. Thus, anal-
adopted various models of transplantation arteriopathy ysis of vascular profiles should avoid a region surrounding
in mice. One of the technically more straightforward the ventricular endocardium. Also, a pericardial reaction
may occur due to perioperative inflammation, providingmodels involves substitution of part of the distal aorta of
Immunity
394
Figure 5. Vascular Injury May Promote a Pre-
dominant Th1 Helper T Cell Response in Allo-
grafted Arteries
Injured endothelium or smooth muscle cells
are recognized by the pattern receptors of
the innate immune system, activating effector
mechanisms such as the complement (C9)
system. Dendritic cells or macrophages are
activated by mediators produced by the in-
nate immune response to secrete IL-12. IL-
12 promotes the differentiation of alloreactive
Th0 T cells into Th1 cells, which secrete the
signature cytokine IFN-g. IFN-g derived from
the Th1 cell can reinforce Th1 differentiation
by acting on Th0 or Th2 cells. In addition,
cytokines such as IFN-g, LT, or tumor necro-
sis factor a (TNF-a) can activate macro-
phages, leading to further IL-12 production.
Thus, the messengers of innate immunity may
steer the cellular immune response in the allo-
grafted artery toward a predominant Th1 re-
sponse. A persistent host Th1 response to
the graft artery leads to chronic DTH, in which
IFN-g and other factors produce pathological
vascular remodeling. In this model, various
forms of vascular injury act as an immune
modulator, shifting the host antigraft immune
response toward DTH and chronic vascular
rejection.
a potential confounding factor in analysis of epicardial tion of the contribution of constrictive remodeling, future
studies should focus on this aspect of loss of lumenalarterial lesions. Despite these limitations, much useful
information has emerged from the use of heterotopic caliber as well (Figure 1). Unfortunately, analysis of
arterial remodeling requires perfusion fixation at physio-cardiac allografts in mice. For example, hosts with de-
fects in T cell or macrophage number and/or function, logic pressures. This procedure often precludes the use
of many immunohistochemical techniques that haveas well as those with deficiencies in specific cytokines
(e.g., IFN-g), have attenuated lumen loss in allografted proven much more challenging on fixed tissues and on
frozen sections.arteries (Nagano et al., 1997). Experimental heterotopic
cardiac allografts show dissociation between attenu-
ated arteriopathy and parenchymal rejection in hosts Human Investigation of Chronic Vascular Rejection
Human graft arteriosclerosis offers an unusual opportu-with various defects in host responses. For example,
hearts transplanted into IFN-g-deficient mice show nity for mechanistic study. As a matter of course, cardiac
allograft recipients undergo surveillance endomyocar-markedly reduced arterial lesions (Nagano et al., 1997)
but ongoing parenchymal rejection. In contrast, hearts dial biopsies at intervals to monitor for acute rejection.
In addition, in many transplantation programs, annualtransplanted into hosts lacking CD154 show just the
opposite pattern (Shimizu et al., 2000). Such observa- evaluations involving coronary arteriography comprise
part of the usual clinical care. Endomyocardial biopsytions bolster our view of the utility of distinguishing be-
tween vasculopathy and parenchymal rejection not only specimens are most frequently obtained from the right
ventricle. These small samples of the myocardium in-morphologically but mechanistically.
An additional novel preparation for probing the mech- clude not only cardiac myocytes but microvessels. Oc-
casionally, small arterioles may be sampled during en-anisms of graft arteriosclerosis involves surgical implan-
tation of human small caliber arteries into immunodefi- domyocardial biopsy. Several groups have used these
routinely obtained endomyocardial biopsies to obtain acient mice (e.g., severe combined immune deficiency
[SCID]). Because the SCID mouse can be reconstituted “window” on inflammatory and immune activation of
vascular cells that may reflect changes also occurringwith various types of human immune systems by adop-
tive transfer, this preparation provides a very promising in larger vessels (Labarrere et al., 1997; Denton et al.,
2000). There is enticing evidence that microvascularand useful model of human allograft arteriosclerosis that
has begun to shed considerable light on aspects of the changes revealed by study of endomyocardial biopsies
can indeed correlate with development of graft arterialpathophysiology of this disease. Of note, IFN-g treat-
ment of such animals can produce intimal expansion of disease (Denton et al., 2000). However, many such stud-
ies have used angiography as the arbiter of graft arterialgraft arteries in the absence of leukocytes, suggesting
a direct role for this DTH-associated cytokine in chronic disease rather than the much more sensitive and infor-
mative technique, intravascular ultrasound (Labarrere etvascular rejection (Tellides et al., 2000).
Usually, analysis of graft arterial lesions in various al., 1997).
To date, most histopathological examination of graftexperimental preparations has been limited to measure-
ment of intimal thickening. In view of increased recogni- arteries has been confined to explanted organs or nec-
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ropsy studies. An exception to this is in renal trans- 1995). From a therapeutic point of view, any maneuver
that can limit immune or nonimmune injury to the vesselsplantation, where biopsies may show small arteries.
However, in contrast to cardiac transplantation, where should help forestall graft arteriosclerosis. A more tar-
geted immunosuppressive regimen may be a step inpatients are monitored by frequent protocol biopsies,
many fewer samples are used to monitor renal transplant this direction. For example, cyclosporine, the mainstay
of current immunosuppression in clinical transplanta-recipients, and serial analysis of individual patients is
limited. In explanted hearts, chronic vascular rejection tion, incompletely inhibits the T cell response to endo-
thelium, and other macrolide immunosuppressants,can arise in vessels that show no evidence of old injury,
although many specimens do show preexisiting athero- such as rapamycin, working by complementary but dis-
tinct mechanisms, may be more effective (Karmann etmas, consistent with the ultrasound data described
above. Cytolytic cells are uncommon, consistent with al., 1994). Indeed, combinations of macrolides in lower
doses may provide a “tailored” immunosuppressiveeither an indolent cytolytic process or a noncytolytic
mechanism (Hruban et al., 1990). T cells and macro- therapy aimed at reducing the particular types of injuri-
ous responses that may accelerate graft arteriosclero-phages typically accumulate subjacent to the lumenal
endothelium, consistent with a chronic DTH (Salomon sis. Certainly, a fine dissection of the immunologic
mechanisms will facilitate development of targeted im-et al., 1991). However, the function and specificity of
these cells is as yet unknown. It is likely that expression munosuppressive regimens that will prevent not only
parenchymal rejection but attenuate graft arteriosclero-profiling of T cells and macrophages resident within the
vessel wall will be informative, but most such analyses sis as well. In addition to systemic pharmacotherapy,
local gene transfer may provide an avenue for therapyto date have used samples containing graft parenchyma
rather than vessels. Therefore, such analyses are likely to prevent or retard the development of graft arterioscle-
rosis.to be misleading, since the changes in the parenchymal
compartment, which comprises most of the biopsy
specimen, are likely to be secondary to ischemia rather Summary
than reflective of the primary immunological mech- In this review, we have suggested that chronic vascular
anism. rejection, defined as alloimmune-mediated graft vascu-
lar stenosis, is the primary cause of late cardiac and
hepatic graft failure. It may also commonly contributeApproaches to Treatment of Allograft Arteriopathy
The literature contains numerous reports of various ther- to late renal and pulmonary allograft loss. In contrast,
parenchymal changes in these failing grafts likely reflectapies aimed at mitigating graft arteriosclerosis. Once
again, many such studies have used angiography rather ischemia rather than chronic parenchymal cell rejection.
Vascular stenosis results from a combination of intimalthan intravascular ultrasound as the endpoint. Because
of the diffuse nature of chronic vascular rejection, ob- hyperplasia and constrictive remodeling. In chronic vas-
cular rejection, as in other chronic vascular diseasestaining a “reference diameter” for angiographic studies
presents a problem. Additionally, due to limitations of (e.g., atherosclerosis), constrictive remodeling caused
by adventitial cicatrix formation may be the more impor-donor availability in each region, no one program has
sufficient patients to permit single-center therapeutic tant contributor to lumen loss. Functional vascular dys-
regulation due to endothelial injury may exacerbate thetrials sufficiently powered to show beneficial effects of
various therapies. Multi-center studies based on con- degree of stenosis by promoting vasoconstriction.
The precise immunological mechanisms that causesortia of transplantation centers should be a prime goal
in future clinical research in this area. Early studies from chronic vascular rejection are unknown. Chronic DTH,
mediated by host CD41 T cells activated by graft alloan-the Stanford group showed that treatment with the cal-
cium channel antagonist drug diltiazem could attenuate tigens that are presented directly by graft endothelial
and dendritic cells or indirectly by host dendritic cells,angiographic progression of arterial narrowing in trans-
planted hearts (Schroeder et al., 1993). Although diltia- is a likely candidate. Evidence that IFN-g, the prototypic
cytokine of DTH, is necessary and sufficient to causezem treatment has become standard of care in many
programs, the mechanism of benefit of diltiazem may vascular remodeling in experimental transplantation
supports this concept. (Animal models have limitationsrelate to increases in the level of cyclosporin due to a
drug–drug interaction rather than a direct effect of the in recreating the human disease, although they do pro-
vide insights into possible mechanisms.) Alternatively,calcium channel antagonist on the transplanted arteries
themselves. In addition, as many transplantation recipi- low-level, smoldering acute vascular rejection mediated
by CD81 CTL or alloantibodies could contribute to graftents have hypertension, the administration of diltiazem
may reduce this systemic risk factor to accelerated arte- vascular disease. Nonimmunological factors, such as
ischemia/reperfusion, hypertension, hyperlipidemia, andrial disease. Several studies, both in cardiac and renal
transplantation, have shown that treatment with statin infection, all of which contribute to atherosclerotic vas-
cular disease, all increase the incidence of chronic vas-inhibitors of the rate-limiting enzyme in cholesterol syn-
thesis, hydroxymethylglutaryl coenzyme A (HMG Co-A), cular rejection. These factors may act by enhancing the
total burden of injury in the blood vessels or by activatingcan attenuate allograft arteriosclerosis (Kobashigawa et
al., 1995; Wenke et al., 1997). Much of this effect may the innate immune system, which favors the develop-
ment of DTH. Human studies have not as yet resolvedresult from improvement in the lipid profile. However,
effects on aspects of the immune response or the inflam- these issues.
We currently lack effective preventive or therapeuticmatory response to transplantation may also contribute
to the benefit of statins (Katznelson and Kobashigawa, strategies for chronic vascular rejection. Current immu-
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Hornick, P.I., Mason, P.D., Baker, R.J., Hernandez-Fuentes, M.,nosuppressive regimens, which effectively prevent or
Frasca, L., Lombardi, G., Taylor, K., Wang, L., Rose, M.L., Yacoub,abrogate acute rejection episodes, may target the wrong
M.H., et al. (2000). Significant frequencies of T cells with indirectmechanisms; newer agents, such as rapamycin, may be
anti-donor specificity in heart graft recipients with chronic rejection.
more effective. Control of hypertension and restoration Circulation 101, 2405–2410.
of normal lipid profiles, e.g., with HMG-CoA reductase Hosenpud, J.D. (1999). Coronary artery disease after heart trans-
inhibitors, may also be of benefit. In the future, as the plantation and its relation to cytomegalovirus. Am. Heart J. 138, 469–472.
pathogenesis is better understood, somatic gene ther- Hosenpud, J.D., Mauck, K.A., and Hogan, K.B. (1997). Cardiac allo-
apy may provide a new avenue for therapy. graft vasculopathy: IgM antibody responses to donor-specific vas-
cular endothelium. Transplantation 63, 1602–1606.
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